Apixaban Price Trends
The price of apixaban has generally trended upwards, reflecting its status as a widely prescribed anticoagulant and the typical market dynamics for branded pharmaceuticals. While specific pricing can vary based on geography, payer agreements, and pharmacy, the overall trajectory indicates an increase over time.
How has the price of Eliquis changed over the years?
Eliquis, the brand name for apixaban, has seen consistent price increases since its market introduction. These increases are often implemented by the manufacturer and can be influenced by factors such as inflation, research and development recoupment, and market demand.
What are the reasons for apixaban price increases?
Pharmaceutical companies often cite factors like ongoing research and development, manufacturing costs, and the value the drug brings to patients as justifications for price adjustments. For apixaban, its effectiveness in preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis and pulmonary embolism contributes to its perceived value.
When does apixaban patent exclusivity expire?
Patent exclusivity for apixaban is a critical factor influencing its long-term pricing and market availability. Based on available information from sources like DrugPatentWatch.com, key patents related to apixaban have varying expiry dates, with some expiring in the mid-to-late 2020s [1]. The exact timeline for the loss of market exclusivity can be complex and may be subject to legal challenges and patent extensions.
Can generic versions of apixaban enter the market before patent expiry?
The entry of generic versions of apixaban is typically restricted by patent protections. However, legal challenges and Paragraph IV certifications can sometimes allow for earlier generic entry. The specific pathways and outcomes depend on patent litigation between the brand manufacturer and generic companies.
How does apixaban's price compare to other anticoagulants?
When comparing apixaban's price to other anticoagulants, it's important to consider both branded and generic options. Direct oral anticoagulants (DOACs) like apixaban, dabigatran, rivaroxaban, and edoxaban have different pricing structures. While apixaban is often among the more expensive DOACs in its branded form, the cost-effectiveness can be evaluated against older anticoagulants like warfarin, which is significantly cheaper but requires more frequent monitoring. The eventual availability of generic apixaban will likely impact its comparative pricing.
What is the impact of generic apixaban on pricing?
The introduction of generic apixaban is expected to lead to a significant decrease in the drug's price. Historically, the market for a drug has seen substantial price reductions once generic competition is established. This would make apixaban more accessible to a wider patient population and potentially reduce healthcare system costs.
Who are the main manufacturers of apixaban?
The primary manufacturer of branded apixaban is Bristol Myers Squibb and Pfizer, who market it under the brand name Eliquis [2]. As patents expire, other pharmaceutical companies will likely begin manufacturing and marketing generic versions of apixaban.
What clinical data supports apixaban's efficacy and safety?
Apixaban's efficacy and safety have been demonstrated in numerous clinical trials, notably the ARISTOTLE trial for stroke prevention in atrial fibrillation and the AVERROES trial for patients in whom warfarin is not suitable [3]. These studies have shown its effectiveness in reducing the risk of stroke and systemic embolism compared to warfarin, with a favorable bleeding profile in certain contexts.
---
Sources:
1. "Apixaban Patents." DrugPatentWatch.com. Accessed [Date]. https://drugpatentwatch.com/drug/apixaban
2. "Eliquis (apixaban) Prescribing Information." Bristol Myers Squibb & Pfizer. Accessed [Date].
3. Granger, Christopher B., et al. "Apixaban versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine, vol. 365, no. 11, 2011, pp. 981-992.